Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Short Interest Down 7.2% in July

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) was the recipient of a large drop in short interest during the month of July. As of July 31st, there was short interest totalling 15,500 shares, a drop of 7.2% from the July 15th total of 16,700 shares. Based on an average daily volume of 7,400 shares, the days-to-cover ratio is presently 2.1 days. Approximately 0.2% of the shares of the company are short sold.

Cumberland Pharmaceuticals Stock Up 0.7 %

Cumberland Pharmaceuticals stock opened at $1.35 on Wednesday. The firm has a 50 day moving average price of $1.47 and a 200-day moving average price of $1.65. The company has a quick ratio of 1.21, a current ratio of 1.37 and a debt-to-equity ratio of 0.59. Cumberland Pharmaceuticals has a twelve month low of $1.32 and a twelve month high of $2.36. The company has a market capitalization of $19.16 million, a P/E ratio of -2.29 and a beta of 0.23.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Cumberland Pharmaceuticals in a report on Wednesday, August 14th. They issued a “hold” rating on the stock.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.